Medtronic Ties Up Cardiac Clearances While MiniMed Exchange Clock Ticks Toward October

Medtronic is spinning off its diabetes business via a MiniMed share swap while collecting FDA and CE wins across cardiac and vascular.

Medtronic has spent the past several weeks working two tracks at once: dismantling one of its oldest business lines while stacking up regulatory wins across its cardiac and vascular franchises. The dual effort is reshaping both the company's portfolio and the story its shareholders are watching.

The stock has been subdued through it all. Shares closed Friday at EUR 76.72, down 0.3% on the day. Over the past 30 days, the decline measures 3.6%, with the equity having shed 5.4% at one point during that stretch.

A Spinoff With a Hard Deadline

At the center of the corporate restructuring sits the separation of the diabetes unit, a process set in motion roughly three weeks ago. Medtronic is offering shareholders the chance to swap their stock for as many as 225,361,295 newly issued MiniMed common shares — a block representing about 80.1% of the diabetes business's total outstanding equity.

The exchange offer runs through October 9, 2026, according to the official mandatory disclosures, with the pricing period slated for October 5 to 7, 2026. The financial terms carry a built-in sweetener: for every $100 of Medtronic common stock accepted in the swap, participants would receive roughly $107.53 in MiniMed shares. That premium comes with a ceiling, however — no more than 4.5939 MiniMed shares per Medtronic share tendered. The combination of the valuation discount, the cap, and the eventual flood of new MiniMed paper in the market is widely seen as a key weight on Medtronic's own quote.

Four Green Lights in Cardiac and Vascular

While the spinoff machinery grinds forward, Medtronic's product pipeline has been collecting approvals on both sides of the Atlantic. On Wednesday, the company disclosed FDA clearance and European CE marking for Affera Prism-2, its cardiac mapping software. The same day brought CE certification for the PulseSelect ProxBox adapter paired with proximity-indicator software. Both tools are aimed at giving electrophysiologists tighter control during procedures treating heart rhythm disorders.

The vascular unit logged its own regulatory milestone Wednesday. The FDA granted Breakthrough Device designation to IN.PACT BTK, an investigational paclitaxel-coated balloon catheter. Medtronic intends to put the device through a randomized pivotal trial, and the designation — part of a US program designed to speed development and review of novel medical technologies — marks a meaningful waypoint toward validating the product's clinical potential.

Billing Codes That Won't Arrive Until 2028

Further out on the horizon, the reimbursement landscape for two Medtronic therapies is being redrawn. The American Medical Association has approved new Category I CPT codes for Altaviva, the implantable tibial neuromodulation device for urge incontinence, and for Symplicity Spyral, the renal denervation system targeting hypertension.

Those codes take effect in January 2028, replacing the interim Category III designations currently in use. According to Medtronic, the upgrade should streamline physician payment and give payers clearer guidance on coverage decisions — though the company notes the codes do not by themselves determine reimbursement.

The regulatory and reimbursement wins, taken together, are steadily laying the technological groundwork for what Medtronic looks like once the diabetes unit is fully carved out.